Advertisement

Drug Discovery for Diabetic Nephropathy: Trying the Leap From Mouse to Man

  • Matthew D. Breyer
    Correspondence
    Address reprint requests to Matthew D. Breyer, MD, Chief Scientific Officer, Lead Generation Biology, Biotechnology Discovery Research, Lilly Research Laboratories, 355 E. Merrill St, Indianapolis, IN 46285
    Affiliations
    Lead Generation Biology, Biotechnology Discovery Research, Lilly Research Laboratories, Indianapolis, IN
    Search for articles by this author

      Summary

      Diabetic nephropathy is the single major cause of kidney failure in the industrialized world and given the emerging global pandemic of diabetes mellitus, its prevalence is expected to only increase. Because of the lack of dynamic biomarkers that define the rate of kidney function loss, there are few proof-of-concept clinical trials for new therapeutics to treat diabetic nephropathy. A molecular understanding of the pathogenesis of diabetic nephropathy also is lacking. These deficiencies are magnified by the fact that most mouse models of diabetic nephropathy fail to show progressive kidney disease. Recently, some mouse models that showed requisite phenotypic changes of diabetic nephropathy have been identified. Validation of results obtained in these experimental models, and showing whether they accurately can predict clinical response to therapeutics in human diabetic nephropathy, must now be established.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Seminars in Nephrology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Foley R.N.
        • Collins A.J.
        The growing economic burden of diabetic kidney disease.
        Curr Diab Rep. 2009; 9: 460-465
        • Gilbertson D.T.
        • Liu J.
        • Xue J.L.
        • Louis T.A.
        • Solid C.A.
        • Ebben J.P.
        • et al.
        Projecting the number of patients with end-stage renal disease in the United States to the year 2015.
        J Am Soc Nephrol. 2005; 16: 3736-3741
        • Brenner B.M.
        • Cooper M.E.
        • de Zeeuw D.
        • Keane W.F.
        • Mitch W.E.
        • Parving H.H.
        • et al.
        Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
        N Engl J Med. 2001; 345: 861-869
        • de Zeeuw D.
        • Agarwal R.
        • Amdahl M.
        • Audhya P.
        • Coyne D.
        • Garimella T.
        • et al.
        Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial.
        Lancet. 2010; 376: 1543-1551
        • Levey A.S.
        • Cattran D.
        • Friedman A.
        • Miller W.G.
        • Sedor J.
        • Tuttle K.
        • et al.
        Proteinuria as a surrogate outcome in CKD: report of a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration.
        Am J Kidney Dis. 2009; 54: 205-226
        • de Zeeuw D.
        • Parekh R.
        • Soman S.
        CKD treatment: time to alter the focus to albuminuria?.
        Adv Chronic Kidney Dis. 2011; 18: 222-223
        • Lewis E.J.
        • Hunsicker L.G.
        • Clarke W.R.
        • Berl T.
        • Pohl M.A.
        • Lewis J.B.
        • et al.
        Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.
        N Engl J Med. 2001; 345: 851-860
        • Logan B.R.
        Optimal two-stage randomized phase II clinical trials.
        Clinical Trials. 2005; 2: 5-12
        • Eijkelkamp W.B.
        • Zhang Z.
        • Remuzzi G.
        • Parving H.H.
        • Cooper M.E.
        • Keane W.F.
        • et al.
        Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial.
        J Am Soc Nephrol. 2007; 18: 1540-1546
        • Yokoyama H.
        • Kanno S.
        • Takahashi S.
        • Yamada D.
        • Honjo J.
        • Saito K.
        • et al.
        Risks for glomerular filtration rate decline in association with progression of albuminuria in type 2 diabetes.
        Nephrol Dial Transplant. 2011; 26: 2924-2930
        • de Zeeuw D.
        • Remuzzi G.
        • Parving H.H.
        • Keane W.F.
        • Zhang Z.
        • Shahinfar S.
        • et al.
        Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy.
        Circulation. 2004; 110: 921-927
        • Heerspink H.J.
        Therapeutic approaches in lowering albuminuria: travels along the renin-angiotensin-aldosterone-system pathway.
        Adv Chronic Kidney Dis. 2011; 18: 290-299
        • Kohan D.E.
        • Pritchett Y.
        • Molitch M.
        • Wen S.
        • Garimella T.
        • Audhya P.
        • et al.
        Addition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy.
        J Am Soc Nephrol. 2011; 22: 763-772
        • Wenzel R.R.
        • Littke T.
        • Kuranoff S.
        • Jurgens C.
        • Bruck H.
        • Ritz E.
        • et al.
        Avosentan reduces albumin excretion in diabetics with macroalbuminuria.
        J Am Soc Nephrol. 2009; 20: 655-664
        • Mehdi U.F.
        • Adams-Huet B.
        • Raskin P.
        • Vega G.L.
        • Toto R.D.
        Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy.
        J Am Soc Nephrol. 2009; 20: 2641-2650
        • Heerspink H.L.
        • Greene T.
        • Lewis J.B.
        • Raz I.
        • Rohde R.D.
        • Hunsicker L.G.
        • et al.
        Effects of sulodexide in patients with type 2 diabetes and persistent albuminuria.
        Nephrol Dial Transplant. 2008; 23: 1946-1954
        • Lewis E.J.
        • Lewis J.B.
        • Greene T.
        • Hunsicker L.G.
        • Berl T.
        • Pohl M.A.
        • et al.
        Sulodexide for kidney protection in type 2 diabetes patients with microalbuminuria: a randomized controlled trial.
        Am J Kidney Dis. 2011; 58: 729-736
        • Mann J.F.
        • Green D.
        • Jamerson K.
        • Ruilope L.M.
        • Kuranoff S.J.
        • Littke T.
        • et al.
        Avosentan for overt diabetic nephropathy.
        J Am Soc Nephrol. 2010; 21: 527-535
        • Sharma K.
        • Ix J.H.
        • Mathew A.V.
        • Cho M.
        • Pflueger A.
        • Dunn S.R.
        • et al.
        Pirfenidone for diabetic nephropathy.
        J Am Soc Nephrol. 2011; 22: 1144-1151
        • Richeldi L.
        • Yasothan U.
        • Kirkpatrick P.
        Pirfenidone.
        Nat Rev Drug Discov. 2011; 10: 489-490
        • Levin A.
        • Beaulieu M.C.
        Trials and tribulations of new agents, novel biomarkers, and retarding renal progression.
        J Am Soc Nephrol. 2011; 22: 992-993
        • Pergola P.E.
        • Raskin P.
        • Toto R.D.
        • Meyer C.J.
        • Huff J.W.
        • Grossman E.B.
        • et al.
        Bardoxolone methyl and kidney function in CKD with type 2 diabetes.
        N Engl J Med. 2011; 365: 327-336
        • Rogacev K.S.
        • Bittenbring J.T.
        • Fliser D.
        Bardoxolone methyl, chronic kidney disease, and type 2 diabetes.
        N Engl J Med. 2011; 365 (author reply, 1746-7): 1745-1746
        • Upadhyay A.
        • Sarnak M.J.
        • Levey A.S.
        Bardoxolone methyl, chronic kidney disease, and type 2 diabetes.
        N Engl J Med. 2011; 365 (author reply, 1746-7): 1746
        • Dinkova-Kostova A.T.
        • Liby K.T.
        • Stephenson K.K.
        • Holtzclaw W.D.
        • Gao X.
        • Suh N.
        • et al.
        Extremely potent triterpenoid inducers of the phase 2 response: correlations of protection against oxidant and inflammatory stress.
        Proc Natl Acad Sci U S A. 2005; 102: 4584-4589
        • Pergola P.E.
        • Krauth M.
        • Huff J.W.
        • Ferguson D.A.
        • Ruiz S.
        • Meyer C.J.
        • et al.
        Effect of bardoxolone methyl on kidney function in patients with T2D and stage 3b-4 CKD.
        Am J Nephrol. 2011; 33: 469-476
        • Wu Q.Q.
        • Wang Y.
        • Senitko M.
        • Meyer C.
        • Wigley W.C.
        • Ferguson D.A.
        • et al.
        Bardoxolone methyl (BARD) ameliorates ischemic AKI and increases expression of protective genes Nrf2, PPARgamma, and HO-1.
        Am J Physiol Renal Physiol. 2011; 300: F1180-F1192
        • Brosius 3rd, F.C.
        • Alpers C.E.
        • Bottinger E.P.
        • Breyer M.D.
        • Coffman T.M.
        • Gurley S.B.
        • et al.
        Mouse models of diabetic nephropathy.
        J Am Soc Nephrol. 2009; 20: 2503-2512
        • Kohan D.E.
        Progress in gene targeting: using mutant mice to study renal function and disease.
        Kidney Int. 2008; 74: 427-437
        • Wendt T.M.
        • Tanji N.
        • Guo J.
        • Kislinger T.R.
        • Qu W.
        • Lu Y.
        • et al.
        RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy.
        Am J Pathol. 2003; 162: 1123-1137
        • Cheng H.
        • Fan X.
        • Moeckel G.W.
        • Harris R.C.
        Podocyte COX-2 exacerbates diabetic nephropathy by increasing podocyte (pro) renin receptor expression.
        J Am Soc Nephrol. 2011; 22: 1240-1251
        • Ziyadeh F.N.
        • Hoffman B.B.
        • Han D.C.
        • Iglesias-De La Cruz M.C.
        • Hong S.W.
        • Isono M.
        • et al.
        Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice.
        Proc Natl Acad Sci U S A. 2000; 97: 8015-8020
        • Berthier C.C.
        • Zhang H.
        • Schin M.
        • Henger A.
        • Nelson R.G.
        • Yee B.
        • et al.
        Enhanced expression of Janus kinase-signal transducer and activator of transcription pathway members in human diabetic nephropathy.
        Diabetes. 2009; 58: 469-477
        • Yang H.
        • Bell T.A.
        • Churchill G.A.
        • Pardo-Manuel de Villena F.
        On the subspecific origin of the laboratory mouse.
        Nat Genet. 2007; 39: 1100-1107
        • Adler A.I.
        • Stevens R.J.
        • Manley S.E.
        • Bilous R.W.
        • Cull C.A.
        • Holman R.R.
        Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64).
        Kidney Int. 2003; 63: 225-232
        • Finne P.
        • Reunanen A.
        • Stenman S.
        • Groop P.-H.
        • Gronhagen-Riska C.
        Incidence of end-stage renal disease in patients with type 1 diabetes.
        JAMA. 2005; 294: 1782-1787
        • Iyengar S.K.
        • Abboud H.E.
        • Goddard K.A.
        • Saad M.F.
        • Adler S.G.
        • Arar N.H.
        • et al.
        Genome-wide scans for diabetic nephropathy and albuminuria in multiethnic populations: the family investigation of nephropathy and diabetes (FIND).
        Diabetes. 2007; 56: 1577-1585
        • Rogus J.J.
        • Poznik G.D.
        • Pezzolesi M.G.
        • Smiles A.M.
        • Dunn J.
        • Walker W.
        • et al.
        High-density single nucleotide polymorphism genome-wide linkage scan for susceptibility genes for diabetic nephropathy in type 1 diabetes: discordant sibpair approach.
        Diabetes. 2008; 57: 2519-2526
        • Breyer M.D.
        • Bottinger E.
        • Brosius 3rd, F.C.
        • Coffman T.M.
        • Harris R.C.
        • Heilig C.W.
        • et al.
        Mouse models of diabetic nephropathy.
        J Am Soc Nephrol. 2005; 16: 27-45
        • Gurley S.B.
        • Mach C.L.
        • Stegbauer J.
        • Yang J.
        • Snow K.P.
        • Hu A.
        • et al.
        Influence of genetic background on albuminuria and kidney injury in Ins2(+/C96Y) (Akita) mice.
        Am J Physiol Renal Physiol. 2010; 298: F788-F795
        • Qi Z.
        • Fujita H.
        • Jin J.
        • Davis L.S.
        • Wang Y.
        • Fogo A.B.
        • et al.
        Characterization of susceptibility of inbred mouse strains to diabetic nephropathy.
        Diabetes. 2005; 54: 2628-2637
        • Kimmelstiel P.
        • Wilson C.
        Intercapillary lesions in the glomeruli of kidney.
        Am J Pathol. 1936; 12: 83-97
        • Wilson J.L.
        • Root H.F.
        • Marble A.
        Diabetic nephropathy; a clinical syndrome.
        N Engl J Med. 1951; 245: 513-517
        • Hudkins K.L.
        • Pichaiwong W.
        • Wietecha T.
        • Kowalewska J.
        • Banas M.C.
        • Spencer M.W.
        • et al.
        BTBR Ob/Ob mutant mice model progressive diabetic nephropathy.
        J Am Soc Nephrol. 2010; 21: 1533-1542
        • Bohle A.
        • Wehrmann M.
        • Bogenschutz O.
        • Batz C.
        • Muller C.A.
        • Muller G.A.
        The pathogenesis of chronic renal failure in diabetic nephropathy.
        Pathol Res Pract. 1991; 187: 251-259
        • White K.E.
        • Bilous R.W.
        Type 2 diabetic patients with nephropathy show structural-functional relationships that are similar to type 1 disease.
        J Am Soc Nephrol. 2000; 11: 1667-1673
        • Zatz R.
        • Dunn B.R.
        • Meyer T.W.
        • Anderson S.
        • Rennke H.G.
        • Brenner B.M.
        Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension.
        J Clin Invest. 1986; 77: 1925-1930
        • Szoka P.R.
        • Paigen K.
        Regulation of mouse major urinary protein production by the Mup-A gene.
        Genetics. 1978; 90: 597-612
        • Sluiter W.
        • Oomens L.W.
        • Brand A.
        • Van Furth R.
        Determination of blood volume in the mouse with 51chromium-labelled erythrocytes.
        J Immunol Methods. 1984; 73: 221-225
        • Yuen P.S.
        • Dunn S.R.
        • Miyaji T.
        • Yasuda H.
        • Sharma K.
        • Star R.A.
        A simplified method for HPLC determination of creatinine in mouse serum.
        Am J Physiol Renal Physiol. 2004; 286: F1116-F1119
        • Takahashi N.
        • Boysen G.
        • Li F.
        • Li Y.
        • Swenberg J.A.
        Tandem mass spectrometry measurements of creatinine in mouse plasma and urine for determining glomerular filtration rate.
        Kidney Int. 2007; 71: 266-271
        • Dunn S.R.
        • Qi Z.
        • Bottinger E.P.
        • Breyer M.D.
        • Sharma K.
        Utility of endogenous creatinine clearance as a measure of renal function in mice.
        Kidney Int. 2004; 65: 1959-1967
        • Keppler A.
        • Gretz N.
        • Schmidt R.
        • Kloetzer H.M.
        • Groene H.J.
        • Lelongt B.
        • et al.
        Plasma creatinine determination in mice and rats: an enzymatic method compares favorably with a high-performance liquid chromatography assay.
        Kidney Int. 2007; 71: 74-78
        • Kemperman F.A.
        • Silberbusch J.
        • Slaats E.H.
        • van Zanten A.P.
        • Weber J.A.
        • Krediet R.T.
        • et al.
        Glomerular filtration rate estimation from plasma creatinine after inhibition of tubular secretion: relevance of the creatinine assay.
        Nephrol Dial Transplant. 1999; 14: 1247-1251
        • Kemperman F.A.
        • Silberbusch J.
        • Slaats E.H.
        • Prins A.M.
        • Weber J.A.
        • Krediet R.T.
        • et al.
        Estimation of the glomerular filtration rate in NIDDM patients from plasma creatinine concentration after cimetidine administration.
        Diabetes Care. 1998; 21: 216-220
        • Eisner C.
        • Faulhaber-Walter R.
        • Wang Y.
        • Leelahavanichkul A.
        • Yuen P.S.
        • Mizel D.
        • et al.
        Major contribution of tubular secretion to creatinine clearance in mice.
        Kidney Int. 2010; 77: 519-526
        • Abrahamson M.
        • Grubb A.
        • Olafsson I.
        • Lundwall A.
        Molecular cloning and sequence analysis of cDNA coding for the precursor of the human cysteine proteinase inhibitor cystatin C.
        FEBS Lett. 1987; 216: 229-233
        • Stevens L.A.
        • Coresh J.
        • Schmid C.H.
        • Feldman H.I.
        • Froissart M.
        • Kusek J.
        • et al.
        Estimating GFR using serum cystatin c alone and in combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD.
        Am J Kidney Dis. 2008; 51: 395-406
        • Hakansson K.
        • Huh C.
        • Grubb A.
        • Karlsson S.
        • Abrahamson M.
        Mouse and rat cystatin C: Escherichia coli production, characterization and tissue distribution.
        Comp Biochem Physiol B Biochem Mol Biol. 1996; 114: 303-311
        • Song S.
        • Meyer M.
        • Turk T.R.
        • Wilde B.
        • Feldkamp T.
        • Assert R.
        • et al.
        Serum cystatin C in mouse models: a reliable and precise marker for renal function and superior to serum creatinine.
        Nephrol Dial Transplant. 2009; 24: 1157-1161
        • Xu Y.
        • Schnorrer P.
        • Proietto A.
        • Kowalski G.
        • Febbraio M.A.
        • Acha-Orbea H.
        • et al.
        IL-10 controls cystatin C synthesis and blood concentration in response to inflammation through regulation of IFN regulatory factor 8 expression.
        J Immunol. 2011; 186: 3666-3673
        • Qi Z.
        • Whitt I.
        • Mehta A.
        • Jin J.
        • Zhao M.
        • Harris R.C.
        • et al.
        Serial determination of glomerular filtration rate in conscious mice using FITC-inulin clearance.
        Am J Physiol Renal Physiol. 2004; 286: F590-F596
        • Zhao H.J.
        • Wang S.
        • Cheng H.
        • Zhang M.Z.
        • Takahashi T.
        • Fogo A.B.
        • et al.
        Endothelial nitric oxide synthase deficiency produces accelerated nephropathy in diabetic mice.
        J Am Soc Nephrol. 2006; 17: 2664-2669
        • Sharma K.
        • McCue P.
        • Dunn S.R.
        Diabetic kidney disease in the db/db mouse.
        Am J Physiol Renal Physiol. 2003; 284: F1138-F1144
        • Huang W.
        • Gallois Y.
        • Bouby N.
        • Bruneval P.
        • Heudes D.
        • Belair M.F.
        • et al.
        Genetically increased angiotensin I-converting enzyme level and renal complications in the diabetic mouse.
        Proc Natl Acad Sci U S A. 2001; 98: 13330-13334
        • Nakagawa T.
        • Sato W.
        • Glushakova O.
        • Heinig M.
        • Clarke T.
        • Campbell-Thompson M.
        • et al.
        Diabetic endothelial nitric oxide synthase knockout mice develop advanced diabetic nephropathy.
        J Am Soc Nephrol. 2007; 18: 539-550
        • Ito T.
        • Tanimoto M.
        • Yamada K.
        • Kaneko S.
        • Matsumoto M.
        • Obayashi K.
        • et al.
        Glomerular changes in the KK-Ay/Ta mouse: a possible model for human type 2 diabetic nephropathy.
        Nephrology (Carlton). 2006; 11: 29-35
        • Zheng S.
        • Noonan W.T.
        • Metreveli N.S.
        • Coventry S.
        • Kralik P.M.
        • Carlson E.C.
        • et al.
        Development of late-stage diabetic nephropathy in OVE26 diabetic mice.
        Diabetes. 2004; 53: 3248-3257
        • da Costa Goncalves A.C.
        • Tank J.
        • Diedrich A.
        • Hilzendeger A.
        • Plehm R.
        • Bader M.
        • et al.
        Diabetic hypertensive leptin receptor–deficient db/db mice develop cardioregulatory autonomic dysfunction.
        Hypertension. 2009; 53: 387-392
        • do Carmo J.M.
        • da Silva A.A.
        • Cai Z.
        • Lin S.
        • Dubinion J.H.
        • Hall J.E.
        Control of blood pressure, appetite, and glucose by leptin in mice lacking leptin receptors in proopiomelanocortin neurons.
        Hypertension. 2011; 57: 918-926